- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00051441
Safety & Efficacy Study of Benzydamine Oral Rinse for the Treatment of Oral Mucositis (Mouth Sores) Resulting From Radiation Therapy for Cancer of the Oral Cavity, Oropharynx, or Nasopharynx
May 17, 2011 updated by: McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
A Double-Blind, Randomized, Vehicle-Controlled Study Comparing the Safety and Efficacy of Benzydamine HCl 0.15% Oral Rinse Including a Separate Open-Label Standard of Care Arm in Subjects With Radiation-Induced Mucositis
The purpose of this study is to compare the effectiveness and safety of benzydamine hydrochloride 0.15% oral rinse to a vehicle oral rinse in the treatment of radiation-induced oral mucositis, and to compare the care normally used for radiation-induced oral mucositis to vehicle oral rinse to ensure that the vehicle does not have detrimental effects on the oral mucosa
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, double-blind, randomized, vehicle-controlled study including an open-label standard of care arm, to determine the effectiveness and safety of benezydamine hydrochloride 0.15% oral rinse as compared with vehicle oral rinse, and vehicle oral rinse as compared to the care normally used in the treatment of radiation-induced oral mucositis.
The hypotheses are that benzydamine hydrochloride 0.15% oral rinse is better than vehicle oral rinse as measured by the proportion of patients reaching a WHO mucositis score of 3 by 5500 cGy and vehicle is no worse than the standard of care as measured by the proportion of patients reaching a WHO mucositis score of 3 by 5500 cGy.
Patients receiving benzydamine hydrochloride 0.15% or vehicle double-blind oral rinses will place 15 mL in the mouth for 2 minutes, gargling for a few seconds at the beginning and end of the rinse, and then expectorate the entire dose.
Dosing with oral rinses will be every 2 - 3 hours while awake for a minimum of 4 times daily to a maximum of 8 times per day.
Double-blind oral rinses will continue daily throughout the duration of the subjects radiation treatment regimen plus 2 additional weeks
Study Type
Interventional
Enrollment (Actual)
605
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Karnofsky performance scale >= 60%
- Diagnosis of pathologically confirmed malignancy involving one or more of the following sites: oral cavity, oropharynx extending down to the level of the supraglottic area, nasopharynx, maxillary sinus and parotid gland
- high risk for developing oral and/or oropharyngeal mucositis due to radiation to head and neck areas
- scheduled to receive a continuous course (eg, often six to eight weeks) of conventional or hyperfractionated external beam radiation for cancer of the head and neck region (subjects who had surgery prior to radiation are eligible) with or without concomitant chemotherapy
- at least two oral tissue sites (not including areas of previous lesions, tumor, surgical resection, or the lips) must be included in the RT treatment volume and planned to receive a total radiation dose of 5500 cGy or higher, given in a single daily fraction of 180 to 220 cGy or twice daily fractions of 110 to 150 cGy
Exclusion Criteria:
- Known hypersensitivity to benzydamine HCl and/or any of the other components including alcohol, menthol, glycerin, flavoring agents, and preservatives
- oral or oropharyngeal mucositis present at the time of entry into the study
- treatment regimen consisting of noncontinuous radiation therapy
- received chemotherapy within 21 days of entry into the study as defined by initiation of radiation
- scheduled to receive or have received brachytherapy
- chronically being medicated for conditions other than tumor-related pain with oral and/or parenteral prescription steroids or analgesics
- use of chlorhexidine gluconate (Peridex), amifostine (Ethyol), topical antibiotics to the mouth (ie, tetracycline), topical steroids to the mouth, povidone iodine rinses, glutamine oral rinses, selective decontamination, and Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF)
- use of mouthwash containing other exclusionary medications and any other medication(s) without an approved indication for topical oral use with the exception of liquid antacid formulations (eg, Maalox, Mylanta)
- participated in an investigational study within 30 days prior to enrolling into the study where an experimental drug and/or product was taken
- not willing and/or able to take opioids for any reason
- cryotherapy (ie, ice chips or popsicles) prior to or during chemotherapy infusion
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
The primary endpoint is the cumulative proportion of patients with severe mucositis (WHO mucositis score of at least 3) at a cumulative radiation dose of 5500 cGy
|
Secondary Outcome Measures
Outcome Measure |
---|
Secondary endpoints include cumulative RT to first use of an opioid for oral mucositis; cumulative RT to first ulceration; cumulative RT to first RT suspension due to oral mucositis
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Completion (Actual)
February 1, 2005
Study Registration Dates
First Submitted
January 9, 2003
First Submitted That Met QC Criteria
January 10, 2003
First Posted (Estimate)
January 13, 2003
Study Record Updates
Last Update Posted (Estimate)
May 19, 2011
Last Update Submitted That Met QC Criteria
May 17, 2011
Last Verified
April 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR002491
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stomatitis
-
Cairo UniversityUnknown
-
Jagiellonian UniversityUnknownDenture StomatitisPoland
-
Qazvin University Of Medical SciencesCompletedDenture StomatitisIran, Islamic Republic of
-
Badr UniversityNot yet recruiting
-
Cairo UniversityUnknown
-
Mashhad University of Medical SciencesCompletedRecurrent Aphthous StomatitisIran, Islamic Republic of
-
Université de MontréalUniversity of Sao PauloCompleted
-
Kafrelsheikh UniversityCompletedAntioxidative Stress | Aphthous Stomatitis, RecurrentEgypt
-
Université de MontréalMcGill UniversityCompleted
Clinical Trials on Benzydamine Hydrochloride 0.15% Oral Rinse
-
Indonesia UniversityCompleted
-
Aziende Chimiche Riunite Angelini Francesco S.p.APPDCompletedHead and Neck Cancer | Radiation-Induced MucositisHungary, Poland
-
Aziende Chimiche Riunite Angelini Francesco S.p.ACross Research S.A.Completed
-
Aziende Chimiche Riunite Angelini Francesco S.p.AZak-Pharma Dienstleistung Ges.m.b.H.CompletedAcute Sore ThroatHungary, Poland, Russian Federation
-
Cairo UniversityNot yet recruiting
-
Sunstar AmericasCompleted
-
Ghada zakiNot yet recruiting
-
Biomedical Development CorporationNational Heart, Lung, and Blood Institute (NHLBI); University of KentuckyUnknownGingivitis | Investigation of Biological Markers of InflammationUnited States
-
Seoul National University HospitalCompletedIntubation ComplicationKorea, Republic of
-
Parion SciencesCompletedSjogren's Syndrome | XerostomiaUnited States